HK13097A - Pharmaceutical preparation and process for its manufacture - Google Patents

Pharmaceutical preparation and process for its manufacture

Info

Publication number
HK13097A
HK13097A HK13097A HK13097A HK13097A HK 13097 A HK13097 A HK 13097A HK 13097 A HK13097 A HK 13097A HK 13097 A HK13097 A HK 13097A HK 13097 A HK13097 A HK 13097A
Authority
HK
Hong Kong
Prior art keywords
manufacture
pharmaceutical preparation
prepn
clodronate
dissolves
Prior art date
Application number
HK13097A
Other languages
English (en)
Inventor
Juhani Posti
Kirsi Katila
Pertti Rantala
Original Assignee
Leiras Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leiras Oy filed Critical Leiras Oy
Publication of HK13097A publication Critical patent/HK13097A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK13097A 1992-04-24 1997-02-05 Pharmaceutical preparation and process for its manufacture HK13097A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9201299A SE501389C2 (sv) 1992-04-24 1992-04-24 Farmaceutiskt preparat och förfarande för dess framställning
PCT/FI1993/000166 WO1993021907A1 (fr) 1992-04-24 1993-04-21 Preparation pharmaceutique et son procede de fabrication

Publications (1)

Publication Number Publication Date
HK13097A true HK13097A (en) 1997-02-14

Family

ID=20386054

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13097A HK13097A (en) 1992-04-24 1997-02-05 Pharmaceutical preparation and process for its manufacture

Country Status (21)

Country Link
US (1) US5525354A (fr)
EP (1) EP0637236B1 (fr)
JP (1) JP3536106B2 (fr)
AT (1) ATE143802T1 (fr)
AU (1) AU671830B2 (fr)
CA (1) CA2134196C (fr)
CZ (1) CZ282871B6 (fr)
DE (2) DE69305335T2 (fr)
DK (1) DK0637236T3 (fr)
EE (1) EE03107B1 (fr)
ES (1) ES2094539T3 (fr)
FI (1) FI110667B (fr)
GR (1) GR3022249T3 (fr)
HK (1) HK13097A (fr)
HU (1) HU219342B (fr)
IL (1) IL105403A (fr)
NO (1) NO306654B1 (fr)
RU (1) RU2116074C1 (fr)
SE (1) SE501389C2 (fr)
TW (1) TW273515B (fr)
WO (1) WO1993021907A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
DE59300688D1 (de) * 1993-05-15 1995-11-02 Boehringer Mannheim Gmbh Tablette mit verbesserter Bioverfügbarkeit enthaltend Dichlormethylendiphosphonsäure als Wirkstoff.
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
FI94926C (fi) * 1993-11-12 1995-11-27 Leiras Oy Menetelmä klodronaattivalmisteen valmistamiseksi
US20010007863A1 (en) 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
FI98343C (fi) * 1995-03-21 1997-06-10 Orion Yhtymae Oy Peroraalinen formulaatio
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
JPH11137208A (ja) * 1997-11-14 1999-05-25 Nikken Chem Co Ltd 口腔内速溶性固形物及びその製造方法
EP0998933A1 (fr) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Procédé pour la préparation de compositions pharmaucetiques contenant des diphosphonates pour administration orale
EP0998932A1 (fr) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Forme d'administration pharmaceutique contenant des diphosphonates ou leurs sels et méthode pour la fabriquer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
ATE386508T1 (de) * 1999-02-22 2008-03-15 Merrion Res I Ltd Feste orale dosierungsform enthaltend einen resorptionsverstärker
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
US6410520B2 (en) 2000-02-01 2002-06-25 The Procter & Gamble Company Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
US6562974B2 (en) 2000-02-01 2003-05-13 The Procter & Gamble Company Process for making geminal bisphosphonates
WO2002092069A1 (fr) 2001-05-11 2002-11-21 Elan Corporation, Plc Renforcateur de permeation
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US20080287400A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645460B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US20080286359A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7862552B2 (en) * 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
KR20110007242A (ko) 2008-05-07 2011-01-21 메리온 리서치 Ⅲ 리미티드 펩티드 조성물 및 그의 제조 방법
DE102008022520A1 (de) * 2008-05-07 2009-11-12 Bayer Animal Health Gmbh Feste Arzneimittelformulierung mit verzögerter Freisetzung
WO2011120033A1 (fr) 2010-03-26 2011-09-29 Merrion Research Iii Limited Compositions pharmaceutiques d'inhibiteurs de facteur xa sélectifs destinées à une administration orale
WO2012094598A2 (fr) 2011-01-07 2012-07-12 Merrion Research Iii Limited Compositions pharmaceutiques de fer pour administration orale
CN107205948B (zh) 2015-01-29 2021-12-14 诺和诺德股份有限公司 包含glp-1激动剂和肠溶衣的片剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57171428A (en) * 1981-04-13 1982-10-22 Sankyo Co Ltd Preparation of coated solid preparation
ATE60711T1 (de) * 1986-12-20 1991-02-15 Boehringer Mannheim Gmbh Clodronat-haltige arzneimittel und verfahren zur herstellung derselben.
JP2782691B2 (ja) * 1987-09-29 1998-08-06 ワーナー−ランバート・コンパニー 腸溶製剤の安定化
FR2629716B1 (fr) * 1988-04-07 1991-07-19 Sanofi Sa Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique

Also Published As

Publication number Publication date
CA2134196C (fr) 2004-02-10
RU94045950A (ru) 1996-11-10
GR3022249T3 (en) 1997-04-30
NO944001D0 (no) 1994-10-21
JPH07505898A (ja) 1995-06-29
FI944961A (fi) 1994-10-21
AU3955093A (en) 1993-11-29
HU9403067D0 (en) 1994-12-28
HUT74572A (en) 1997-01-28
JP3536106B2 (ja) 2004-06-07
TW273515B (fr) 1996-04-01
IL105403A0 (en) 1993-08-18
AU671830B2 (en) 1996-09-12
SE9201299L (sv) 1993-10-25
IL105403A (en) 1998-03-10
EP0637236B1 (fr) 1996-10-09
RU2116074C1 (ru) 1998-07-27
DK0637236T3 (da) 1997-03-17
NO306654B1 (no) 1999-12-06
SE9201299D0 (sv) 1992-04-24
CZ282871B6 (cs) 1997-11-12
DE69305335T2 (de) 1997-04-30
DE69305335D1 (de) 1996-11-14
EP0637236A1 (fr) 1995-02-08
HU219342B (en) 2001-03-28
ATE143802T1 (de) 1996-10-15
FI944961A0 (fi) 1994-10-21
DE637236T1 (de) 1995-07-06
ES2094539T3 (es) 1997-01-16
NO944001L (no) 1994-10-21
WO1993021907A1 (fr) 1993-11-11
US5525354A (en) 1996-06-11
EE03107B1 (et) 1998-08-17
CZ261494A3 (en) 1995-02-15
FI110667B (fi) 2003-03-14
SE501389C2 (sv) 1995-01-30
CA2134196A1 (fr) 1993-11-11

Similar Documents

Publication Publication Date Title
GR3022249T3 (en) Pharmaceutical preparation and process for its manufacture.
ES2130278T3 (es) Preparacion de morfina de liberacion controlada.
FI960851A (fi) Menetelmä N-amino-1-hydroksi-alkylideeni-1,1-bisfosfonihappojen valmistamiseksi
ES2144077T3 (es) Formas de administracion que contienen sales solidas de acido r-tioctico con liberacion y biodisponibilidad mejoradas.
CA2125662A1 (fr) Systeme a administration transdermique contenant de l'acide acetylsalicylique pour le traitement de la thrombose et la prophylaxie du cancer
HK1005425A1 (en) Use of 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the manufacture of a medicament for the treatment of restenosis
DE69631609D1 (en) Tricyclische erythromycinderivate
AU4702093A (en) More easily biologically absorbed tablet containing dichloromethylene diphosphonic acid as the active agent
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
EP0824341A4 (fr) Prevention des pertes de dnets par l'administration d'alendronate ou de ses sels
CA2057456A1 (fr) Produit pharmaceutique contre la depression

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090421